Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29396897 | 1.00 | — | — | |
| SCHEMBL30629 | 0.97 | — | — | |
| Bromide SCHEMBL11867173 | 0.94 | — | — | |
| Acetic Acid SCHEMBL16792627 | 0.88 | FFAR3 (0.39) | — | |
| Acrylic Acid SCHEMBL1399512 | 0.80 | LMNA (0.46) | — | |
| Methacrylic Acid SCHEMBL1399641 | 0.80 | TDP1 (0.42) | — | |
| Trifluoroacetic Acid SCHEMBL4276694 | 0.80 | CHIT1 (0.35) | — | |
| SCHEMBL14590056 | 0.78 | CA1 (0.41) | — | |
| Beta-Alanine SCHEMBL3198735 | 0.78 | LMNA (0.41) | — | |
| SCHEMBL6039526 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | claimed |
| CN-112552201-A | acryloyl-N-methyl substituted glycinamide monomer and preparation method thereof | 天津大学 | 2021-03-26 | — | — | CN | claimed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2025226545-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | disclosed |
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-113563244-B | Substituted aza five-membered ring compound and application thereof in medicine | 广东东阳光药业股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-3468953-B1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| WO-2006072370-A1 | SELECTED BENZOFURAN DERIVATIVES | ARPIDA AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| US-20060128613-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2006-06-15 | — | — | US | disclosed |
| WO-2006040666-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-04-20 | — | — | WO | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
| WO-2004087677-A2 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |